#ASH18: Leg­end Biotech — al­lied with J&J now — con­tin­ues to wow the crowd with their BC­MA CAR-T up­date. What will blue­bird say?

Back in the sum­mer of 2017, an un­known Chi­nese biotech called Leg­end jumped in­to AS­CO and dis­rupt­ed the rep blue­bird had care­ful­ly erect­ed for it­self as the break­away leader among com­pa­nies de­vel­op­ing a BC­MA-tar­get­ing CAR-T for mul­ti­ple myelo­ma, of­fer­ing up reg­u­lar looks at one of the in­dus­try’s top de­vel­op­ment pro­grams.

Leg­end of­fered star­tling proof-of-con­cept da­ta to sug­gest that they could leapfrog the pack and land among the top com­pa­nies pi­o­neer­ing the field. Soon af­ter J&J fol­lowed up with a rich $350 mil­lion cash up­front to part­ner with Leg­end, of­fer­ing their en­dorse­ment that the biotech was no fly-by-night pre­tender to the throne.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER